Pharmacogenetic Correlates of Antipsychotic-Induced Weight Gain in the Chinese Population

Chao Luo1,2,3 • Junyan Liu4 • Xu Wang1,2 • Xiaoyuan Mao1,2 • Honghao Zhou1,2,5 • Zhaoqian Liu1,2,5,*
1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China
2Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha 410078, China
3School of Life Sciences, Central South University, Changsha 410078, China
4Department of Orthopaedics, The First Affiliated Hospital of the University of South China, Hengyang 421001, China
5National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China


Antipsychotic-induced weight gain (AIWG) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. We aimed to review the progress of pharmacogenetic studies on AIWG in the Chinese population to compare the results for Chinese with other ethnic populations, identify the limitations and problems of current studies, and provide future research directions in China. Both English and Chinese electronic databases were searched to identify eligible studies. We determined that > 25 single-nucleotide polymorphisms in 19 genes have been investigated in association with AIWG in Chinese patients over the past few decades. HTR2C rs3813929 is the most frequently studied single-nucleotide polymorphism, and it seems to be the most strongly associated with AIWG in the Chinese population. However, many genes that have been reported to be associated with AIWG in other ethnic populations have not been included in Chinese studies. To explain the pharmacogenetic reasons for AIWG in the Chinese population, genome-wide association studies and multiple-center, standard, unified, and large samples are needed.


Pharmacogenetic; Antipsychotic; Weight gain; Single nucleotide polymorphism; Schizophrenia


Browse: 1